Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Adalimumab versus Infliximab Treatment Outcome in Ulcerative Colitis: Application of EQ-5D, Visual Analogue Scale, and IBDQ-9 Measures: A Prospective Observational Study

Author(s): Hassan Karami, Farbod Ebadi Fard Azar*, Kamran Bagheri Lankarani, Aziz Rezapour, Sulmaz Ghahramani and Abdolvahab Baghbanian

Volume 18, Issue 4, 2023

Published on: 27 August, 2022

Page: [484 - 495] Pages: 12

DOI: 10.2174/1574886317666220526153518

Price: $65

Abstract

Background: Ulcerative colitis (UC) is a chronic global disease, and its incidence and prevalence are increasing worldwide.

Objective: Our objective was to compare the secondary outcome of treatment with Infliximab (IFX) and Adalimumab (ADA) in the UC patients.

Methods: This was a one-year prospective observational study of moderate- to -severe UC patients treated with ADA or IFX. Patients' secondary health outcomes were measured using the EQ-5D 3L, EQ-VAS, and IBDQ-9 tools. T-test, Mann-Whitney, chi-square, and Fisher's exact tests were used to compare health-related quality of life (HRQoL) among UC patients. HRQoL predictor variables were identified by multivariate linear regression and multivariate logistic regression.

Results: A total of 238 UC patients (patients taking IFX: 78, patients taking ADA: 160) with a mean age of 37.66 and a mean disease duration of 9.29 years were enrolled. The EQ-5D index, EQ-VAS, and IBDQ-9 scores of patients taking IFX were 0.65, 55.93 and, 37.42, respectively. Similarly, patients taking ADA were 0.68, 59.27 and, 36.61, respectively. The highest problem reports were in P/D: 86.1% and A/D: 73.5%. The main independent predictors of HRQoL were: education over 12 years (β = 0.054 [EQ-5D index], β = 13.63 [EQ-VAS], OR: 0.28 [MO], OR: 0.07 [SC]), education between 6-12 years (β = 11.23 [EQ-VAS]), and having "other chronic diseases" (β = -0.074 [EQ-5D index], β = -5.29 [IBDQ-9], OR: 2.84 [UA], OR: 3.80 [A/D]).

Conclusion: There was no significant difference between the effect of ADA and IFX on secondary health outcomes in patients with moderate-to-severe UC.

Keywords: Infliximab, Adalimumab, Ulcerative colitis, EQ-5D, Iran, Health-related quality of life

« Previous Next »
[1]
Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: A cross-sectional, observational study. J Crohn’s Colitis 2014; 8(7): 598-606.
[http://dx.doi.org/10.1016/j.crohns.2013.11.017] [PMID: 24345767]
[2]
Molodecky N A, Soon S, Rabi D M, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142(1): 46-54.
[http://dx.doi.org/10.1053/j.gastro.2011.10.001]
[3]
Gholamrezaei A, Haghdani S, Shemshaki H, Tavakoli H, Emami MH. Linguistic validation of the inflammatory bowel disease questionnaire-short form (IBDQ-9) in Iranian population. majallah-i danishkadah-i pizishki-i isfahan 2011; 28(123): 1-10.
[4]
Iglesias M, Vázquez I, Barreiro-de Acosta M, et al. Health related quality of life in patients with Cohn´s disease in remission. Rev Esp Enferm Dig 2010; 102(11): 624-30.
[http://dx.doi.org/10.4321/S1130-01082010001100002] [PMID: 21142382]
[5]
Casellas F, Robles V, Borruel N, et al. Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment. J Crohn’s Colitis 2012; 6(9): 881-6.
[http://dx.doi.org/10.1016/j.crohns.2012.01.019] [PMID: 22398074]
[6]
Poole CD, Connolly MP, Nielsen SK, Currie CJ, Marteau P. A comparison of physician-rated disease severity and patient reported outcomes in mild to moderately active ulcerative colitis. J Crohn’s Colitis 2010; 4(3): 275-82.
[http://dx.doi.org/10.1016/j.crohns.2009.11.010] [PMID: 21122516]
[7]
Drummond MF, McGuire A. Economic evaluation in health care: Merging theory with practice. New York: Oxford University Press 2001.
[8]
National institute for health and care excellence. NICE process and methods guides guide to the methods of technology Appraisal 2013. London 2013.
[9]
Hlavaty T, Persoons P, Vermeire S, et al. Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn’s disease. Inflamm Bowel Dis 2006; 12(3): 199-204.
[http://dx.doi.org/10.1097/01.MIB.0000217768.75519.32] [PMID: 16534421]
[10]
Meijs S, Gardenbroek TJ, Sprangers MA, et al. Health-related quality of life and disability in patients with ulcerative colitis and proctocolectomy with ileoanal pouch versus treatment with anti-TNF agents. J Crohn’s Colitis 2014; 8(7): 686-92.
[http://dx.doi.org/10.1016/j.crohns.2013.12.011] [PMID: 24418659]
[11]
Yu H, MacIsaac D, Wong JJ, et al. Market share and costs of biologic therapies for inflammatory bowel disease in the USA. Aliment Pharmacol Ther 2018; 47(3): 364-70.
[http://dx.doi.org/10.1111/apt.14430] [PMID: 29164650]
[12]
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23): 2462-76.
[http://dx.doi.org/10.1056/NEJMoa050516] [PMID: 16339095]
[13]
Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Results of a randomised controlled trial. Gut 2011; 60(6): 780-7.
[http://dx.doi.org/10.1136/gut.2010.221127] [PMID: 21209123]
[14]
Zhang Y, Coello PA, Brożek J, et al. Using patient values and preferences to inform the importance of health outcomes in practice guideline development following the GRADE approach. Health Qual Life Outcomes 2017; 15(1): 52.
[http://dx.doi.org/10.1186/s12955-017-0621-0] [PMID: 28460638]
[15]
Postmus D, Mavris M, Hillege HL, et al. Incorporating patient preferences into drug development and regulatory decision making: Results from a quantitative pilot study with cancer patients, carers, and regulators. Clin Pharmacol Ther 2016; 99(5): 548-54.
[http://dx.doi.org/10.1002/cpt.332] [PMID: 26715217]
[16]
Bastemeijer CM, Voogt L, van Ewijk JP, Hazelzet JA. What do patient values and preferences mean? A taxonomy based on a systematic review of qualitative papers. Patient Educ Couns 2017; 100(5): 871-81.
[http://dx.doi.org/10.1016/j.pec.2016.12.019] [PMID: 28043713]
[17]
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. Ulcerative colitis care pathway. Gastroenterology 2015; 149(1): 238-45.
[http://dx.doi.org/10.1053/j.gastro.2015.05.036] [PMID: 26025078]
[18]
Hagelund LM, Elkjær Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin 2020; 36(5): 771-9.
[http://dx.doi.org/10.1080/03007995.2020.1716704] [PMID: 31944145]
[19]
Rubin DT, Siegel CA, Kane SV, et al. Impact of ulcerative colitis from patients’ and physicians’ perspectives: Results from the UC: NORMAL survey. Inflamm Bowel Dis 2009; 15(4): 581-8.
[http://dx.doi.org/10.1002/ibd.20793] [PMID: 19067414]
[20]
Schreiber S, Panés J, Louis E, Holley D, Buch M, Paridaens K. Perception gaps between patients with ulcerative colitis and healthcare professionals: An online survey. BMC Gastroenterol 2012; 12(1): 108.
[http://dx.doi.org/10.1186/1471-230X-12-108] [PMID: 22894661]
[21]
Petrak F, Hardt J, Clement T, Börner N, Egle UT, Hoffmann SO. Impaired health-related quality of life in inflammatory bowel diseases: Psychosocial impact and coping styles in a national German sample. Scand J Gastroenterol 2001; 36(4): 375-82.
[http://dx.doi.org/10.1080/003655201300051171] [PMID: 11336162]
[22]
Levenstein S, Li Z, Almer S, et al. Cross-cultural variation in disease-related concerns among patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96(6): 1822-30.
[http://dx.doi.org/10.1111/j.1572-0241.2001.03878.x] [PMID: 11419836]
[23]
Group TE. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy 1990; 16(3): 199-208.
[http://dx.doi.org/10.1016/0168-8510(90)90421-9] [PMID: 10109801]
[24]
Goudarzi R, Sari AA, Zeraati H, Rashidian A, Mohammad K, Amini S. Valuation of quality weights for EuroQol 5-dimensional health states with the time trade-off method in the capital of Iran. Value Health Reg Issues 2019; 18: 170-5.
[http://dx.doi.org/10.1016/j.vhri.2019.01.007] [PMID: 31096140]
[25]
Zare F, Ameri H, Madadizadeh F, Aghaei MR. Validity and reliability of the EQ-5D-3L (a generic preference-based instrument used for calculating quality-adjusted life -years) for patients with type 2 diabetes in Iran. Diabetes Metab Syndr 2021; 15(1): 319-24.
[http://dx.doi.org/10.1016/j.dsx.2021.01.009] [PMID: 33486224]
[26]
Stark RG, Reitmeir P, Leidl R, König H-H. Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany. Inflamm Bowel Dis 2010; 16(1): 42-51.
[http://dx.doi.org/10.1002/ibd.20989] [PMID: 19475674]
[27]
Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease. Aliment Pharmacol Ther 2009; 29(9): 1032-41.
[http://dx.doi.org/10.1111/j.1365-2036.2009.03966.x] [PMID: 19222413]
[28]
Casellas F, Alcalá M-J, Prieto L, Miró J-RA, Malagelada J-R. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am J Gastroenterol 2004; 99(3): 457-61.
[http://dx.doi.org/10.1111/j.1572-0241.2004.04071.x] [PMID: 15056085]
[29]
Huamán JW, Casellas F, Borruel N, et al. Cutoff values of the Inflammatory Bowel Disease Questionnaire to predict a normal health related quality of life. J Crohn’s Colitis 2010; 4(6): 637-41.
[http://dx.doi.org/10.1016/j.crohns.2010.07.006] [PMID: 21122573]
[30]
Sherman M, Tsynman DN, Kim A, et al. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy. J Dig Dis 2014; 15(4): 174-9.
[http://dx.doi.org/10.1111/1751-2980.12125] [PMID: 24373601]
[31]
Karami H, Shirvani Shiri M, Rezapour A, Sarvari Mehrabadi R, Afshari S. The association between diabetic complications and health-related quality of life in patients with type 2 diabetes: A cross-sectional study from Iran. Qual Life Res 2021; 30(7): 1963-74.
[http://dx.doi.org/10.1007/s11136-021-02792-7] [PMID: 33900519]
[32]
Javanbakht M, Keshtkaran A, Shabaninejad H, Karami H, Zakerinia M, Delavari S. Comparison of blood transfusion plus chelation therapy and bone marrow transplantation in patients with β-thalassemia: Application of SF-36, EQ-5D, and visual analogue scale measures. Int J Health Policy Manag 2015; 4(11): 733-40.
[http://dx.doi.org/10.15171/ijhpm.2015.113] [PMID: 26673333]
[33]
Moradi M, Rencz F, Brodszky V, Moradi A, Balogh O, Gulácsi L. Health status and quality of life in patients with psoriasis: An Iranian cross-sectional survey. Arch Iran Med 2015; 18(3)
[34]
Parra RS, Chebli JMF, Amarante HMBS, et al. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil. World J Gastroenterol 2019; 25(38): 5862-82.
[http://dx.doi.org/10.3748/wjg.v25.i38.5862] [PMID: 31636478]
[35]
Nordin K, Påhlman L, Larsson K, Sundberg-Hjelm M, Lööf L. Health-related quality of life and psychological distress in a population-based sample of Swedish patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37(4): 450-7.
[http://dx.doi.org/10.1080/003655202317316097] [PMID: 11989837]
[36]
Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: Psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis 2005; 11(10): 909-18.
[http://dx.doi.org/10.1097/01.mib.0000179467.01748.99] [PMID: 16189421]
[37]
Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol 2010; 16(25): 3168-77.
[http://dx.doi.org/10.3748/wjg.v16.i25.3168] [PMID: 20593502]
[38]
Del Hoyo J, Nos P, Faubel R, et al. A web-based telemanagement system for improving disease activity and quality of life in patients with complex inflammatory bowel disease: Pilot randomized controlled trial. J Med Internet Res 2018; 20(11): e11602.
[http://dx.doi.org/10.2196/11602] [PMID: 30482739]
[39]
Sandborn WJ, Sakuraba A, Wang A, et al. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States. Curr Med Res Opin 2016; 32(7): 1233-41.
[http://dx.doi.org/10.1185/03007995.2016.1168290] [PMID: 26986449]
[40]
Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: Long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32(4): 522-8.
[http://dx.doi.org/10.1111/j.1365-2036.2010.04380.x] [PMID: 20500733]
[41]
Han M, Jung YS, Cheon JH, Park S. Comparison of real-world outcomes of infliximab versus adalimumab in biologic-naïve Korean patients with ulcerative colitis: A population-based study. Yonsei Med J 2020; 61(1): 48-55.
[http://dx.doi.org/10.3349/ymj.2020.61.1.48] [PMID: 31887799]
[42]
Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of long-term outcomes of infliximab versus adalimumab treatment in biologic-naïve patients with ulcerative colitis. Gut Liver 2021; 15(2): 232-42.
[http://dx.doi.org/10.5009/gnl19433] [PMID: 32616683]
[43]
Burisch J, Weimers P, Pedersen N, et al. Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with inflammatory bowel disease--an ECCO-EpiCom study. J Crohn’s Colitis 2014; 8(9): 1030-42.
[http://dx.doi.org/10.1016/j.crohns.2014.01.028] [PMID: 24560877]
[44]
Severs M, Mangen MJJ, Fidder HH, et al. Clinical predictors of future nonadherence in inflammatory bowel disease. Inflamm Bowel Dis 2017; 23(9): 1568-76.
[http://dx.doi.org/10.1097/MIB.0000000000001201] [PMID: 28700534]
[45]
AlRuthia Y, Almadi M, Aljebreen A, et al. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia. J Med Econ 2020; 23(10): 1102-10.
[http://dx.doi.org/10.1080/13696998.2020.1791889] [PMID: 32619388]
[46]
Casellas F, López-Vivancos J, Casado A, Malagelada J-R. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res 2002; 11(8): 775-81.
[http://dx.doi.org/10.1023/A:1020841601110] [PMID: 12482161]
[47]
Guthrie E, Jackson J, Shaffer J, Thompson D, Tomenson B, Creed F. Psychological disorder and severity of inflammatory bowel disease predict health-related quality of life in ulcerative colitis and Crohn’s disease. Am J Gastroenterol 2002; 97(8): 1994-9.
[http://dx.doi.org/10.1111/j.1572-0241.2002.05842.x] [PMID: 12190166]
[48]
Min Ho PY, Hu W, Lee YY, et al. Health-related quality of life of patients with inflammatory bowel disease in Singapore. Intest Res 2019; 17(1): 107-18.
[http://dx.doi.org/10.5217/ir.2018.00099] [PMID: 30419638]
[49]
Hjortswang H, Järnerot G, Curman B, et al. The influence of demographic and disease-related factors on health-related quality of life in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 2003; 15(9): 1011-20.
[http://dx.doi.org/10.1097/00042737-200309000-00012] [PMID: 12923375]
[50]
Hjortswang H, Ström M, Almer S. Health-related quality of life in Swedish patients with ulcerative colitis. Am J Gastroenterol 1998; 93(11): 2203-11.
[http://dx.doi.org/10.1111/j.1572-0241.1998.00537.x] [PMID: 9820397]

Rights & Permissions Print Cite
Article Metrics
9
© 2024 Bentham Science Publishers | Privacy Policy